Navigation Links
IDM Pharma Announces IDM-2101 Updated Phase 2 Results Show Treatment Well Tolerated With Positive Survival Trend in Lung Cancer Patients
Date:11/2/2007

ch 2006.

Updated one-year survival in patients treated with IDM-2101 was 60 percent, compared to 49 percent in a group of seventy-two patients who were HLA-A2 negative but otherwise comparable (external comparator group). Median survival for patients treated with IDM-2101 was 17.3 months compared to 12.0 months for patients in the comparator group. Ninety-one percent of patients treated with IDM-2101, who were tested for immune response, had a measurable response to at least one of the epitopes included in the vaccine with 64 percent responding to at least three of the epitopes. Toxicities attributable to the vaccine were mild and consisted primarily of injection site reactions.

"We are very encouraged by the continued positive survival trend and safety results of IDM-2101 in this study and are eager to continue development of this novel treatment," said Timothy P. Walbert, president and chief executive officer, IDM Pharma, Inc. "We will move forward with our plan to use the final results from this trial, which we expect next year, as a basis in determining an appropriate clinical pathway for IDM-2101."

About IDM-2101

IDM-2101 includes nine CTL epitopes from four tumor associated antigens (TAA) including two proprietary native epitopes and seven modified, or analog, epitopes and one universal epitope a source of T-cell help. Tolerance to TAA, which is a failure of the immune system to recognize the cancer as diseased tissue, is broken by using these analog epitopes which enhance the potency of the T cell response. The Phase 2 IDM-2101 study has been ongoing since late 2004 and the last patient is expected to be treated in May 2008.

About Lung Cancer

Lung cancer continues to be a major health problem with a very high mortality rate and represents the leading cause of cancer death in the United States. According to the American Cancer Society, approximately 213,000 new lung cancer cases will be diagnosed in the United States in 2007
'/>"/>

SOURCE IDM Pharma, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Sygnis Pharma AG announces date for presentation of clinical results
2. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
3. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
4. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
5. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
6. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
7. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
8. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
9. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
10. Array BioPharma to Present at the C.E Unterbeg, Towbin Emerging Growth Conference
11. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... Dec. 19, 2014 You,re visiting the dentist ... cleaning when he or she says you need a ... before, you may have several questions and feel apprehensive ... to know it,s nothing to worry about. The Pennsylvania ... and alleviate any anxiety the public may have surrounding ...
(Date:12/19/2014)... , Dec. 19, 2014   Hospira, Inc. ... of injectable drugs and infusion technologies, today announced that ... Annual Healthcare Conference on Wednesday, Jan. 14, 2015, in ... scheduled to begin at 10:30 a.m. Pacific time on ... all interested parties through a live audiocast accessible via ...
(Date:12/19/2014)... , Dec. 19, 2014  Monarch America Inc. ... Kinetics Corp.) is pleased to provide this review of ... growth in 2015. "Over this past year, ... and I am extremely proud to say that Monarch ... today than it has ever been," stated Eric ...
Breaking Medicine Technology:Root Canals Have Become More Routine 2Monarch America Inc. CEO Reviews Recent Achievements and Provides Outlook for 2015 2Monarch America Inc. CEO Reviews Recent Achievements and Provides Outlook for 2015 3
... HONG KONG, July 18, 2011 Data from high-risk ... due to nondeferrable, non-cardiac surgery show good short- and ... Genous Stent, according to a study published online on ... In the single-center study, patients treated with ...
... Inc. (NASDAQ: OPTR ) today announced the ... of Clostridium difficile -associated diarrhea (CDAD) in patients ... Phase 3 clinical studies, DIFICID had clinical response rates ... were non-inferior to oral vancomycin. In addition, DIFICID was ...
Cached Medicine Technology:OrbusNeich's Genous™ Stent Enables Early and Safe Discontinuation of Dual Antiplatelet Therapy in High-Risk Patients Requiring Nondeferrable, Non-Cardiac Surgery 2OrbusNeich's Genous™ Stent Enables Early and Safe Discontinuation of Dual Antiplatelet Therapy in High-Risk Patients Requiring Nondeferrable, Non-Cardiac Surgery 3Optimer Launches DIFICID™ (fidaxomicin) Tablets for Treatment of Clostridium Difficile-Associated Diarrhea (CDAD) in Patients 18 Years of Age and Older 2Optimer Launches DIFICID™ (fidaxomicin) Tablets for Treatment of Clostridium Difficile-Associated Diarrhea (CDAD) in Patients 18 Years of Age and Older 3Optimer Launches DIFICID™ (fidaxomicin) Tablets for Treatment of Clostridium Difficile-Associated Diarrhea (CDAD) in Patients 18 Years of Age and Older 4Optimer Launches DIFICID™ (fidaxomicin) Tablets for Treatment of Clostridium Difficile-Associated Diarrhea (CDAD) in Patients 18 Years of Age and Older 5
(Date:12/22/2014)... Naples, Florida (PRWEB) December 22, 2014 ... this holiday season, the gift of health and vitality. ... is offering its three top-selling anti-aging formulas in special ... with free rush delivery. , Each bottle contains ... digestion, areas that don't work as well as we ...
(Date:12/22/2014)... 2014 Xarelto Lawsuit News : ... judges has granted a request to centralize pending and ... Court, Eastern District of Louisiana. The U.S. Judicial Panel ... 12 to transfer over 50 Xarelto cases–21 lawsuits and ... Louisiana court for consolidation under U.S. District Judge Eldon ...
(Date:12/22/2014)... December 22, 2014 Christmas is days away, ... a fast and easy solution that will please: the ... be purchased from from $25 up to $350," says Kathy ... customer satisfaction and a wide array of skin care products ... and no expiration dates. , Gift delivery past shipping ...
(Date:12/22/2014)... The NLN’s 2015 Leadership ... this month. Faculty have been selected through competitive ... fast-tracked for administrative leadership roles within their academic ... Simulation Educators, featuring a curriculum uniquely devised for ... , Twenty nurse educators were chosen for ...
(Date:12/21/2014)... Recently, BambooFlooringChina.com, a famous bamboo lumber supplier, has ... and launched a bamboo flooring promotion with great discounts, ... 30, 2015. , According to the CEO of the ... available today; it has a highly distinctive grain with ... woven bamboo is made by a unique manufacturing process ...
Breaking Medicine News(10 mins):Health News:You Still Have Time to Give the Gift of Health and Vitality to a Mature Loved One 2Health News:Panel Orders Xarelto Lawsuits Consolidated Into Multi-District Litigation Reports Alonso Krangle LLP 2Health News:Panel Orders Xarelto Lawsuits Consolidated Into Multi-District Litigation Reports Alonso Krangle LLP 3Health News:Panel Orders Xarelto Lawsuits Consolidated Into Multi-District Litigation Reports Alonso Krangle LLP 4Health News:NLN Leadership Institute Announces 2015 Cohorts 2Health News:NLN Leadership Institute Announces 2015 Cohorts 3Health News:BambooFlooringChina.com Announced Its Durable Strand Woven Bamboo Flooring Collection 2
... governing the private educational institutions in the state in ... cabinet decided to adopt the new rules for the ... said here. ,The school managements will now ... prescribed and timely salaries to teaching and non-teaching staff ...
... drink and the sparkle of many a party. That apart, wine ... a health drink, known to sustain cardiovascular// health and keep age ... health, it is cheers to a copious flow of health benefits. ... wine is considered sacrosanct, alluding to the blood of Christ, which ...
... Chapel Hill suggested that low LDL values can increase ... for low density lipoprotein; the low values of LDL ... been made between LDL and cardiovascular diseases, smoking and ... a lower occurrence of heart attack and stroke than ...
... “trans fat” leaves a bad taste in the mouths ... for health, but// scientists at the University of Arkansas ... by juggling the molecular structure of soy oil. ... student Vishal Jain produced soy oil rich in conjugated ...
... are the best ways to prevent the most common types ... paediatricians.// ,Kidney stones are rarely a serious condition, ... infections. Signs and symptoms of kidney stones include intense pain ... painful urination, blood in the urine and/or cloudy urine, urinary ...
... progression of Alzheimer's disease (AD) according to a study ... is one// in a group of related steroid hormones ... published in the December 20 issue of The Journal ... testosterone loss and AD, which affects 4.5 million Americans. ...
Cached Medicine News:Health News:Celebrating Christmas With Wine – The Elixir of the God 2Health News:Celebrating Christmas With Wine – The Elixir of the God 3Health News:Low LDL Levels Lead to Parkinson's Disease 2Health News:Healthy Potato Chips: A Trans Fat Oil With Health Benefits 2Health News:Drinking Plenty of Water may Prevent Kidney Stones 2Health News:Increase Testosterone Levels To Slow Down Alzheimer’ 2
Prolactin EIA Reproductive Markers 025-BC-1037...
LH EIA Reproductive Markers 025-BC-1031 Luteinizing Hormone...
... follows the basic principle of a competitive ... an unlabeled antigen and an labelled antigen ... a specific antiserum . The amount of ... to the antibody is inversely proportional to ...
... (5-Androstene-3-0L-17-one,Androstenolone, Dehydroisoandrosterone,Transdehydroandrosterone, DHEA) is a ... mostly in its,sulfate form (DHEA-S). ... based on the competition principle ... amount of DHEA-S present in ...
Medicine Products: